Aligos Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue from collaborations | $— | $334 |
| Revenue from customers | 2,186 | 3,611 |
| Operating expenses: | ||
| Research and development | 69,453 | 70,269 |
| General and administrative | 20,718 | 22,830 |
| Total operating expenses | 90,171 | 93,099 |
| Loss from operations | (87,985) | (89,154) |
| Interest and other income, net | 3,922 | 4,406 |
| Change in fair value of 2023 Common Warrants | 60,184 | (46,132) |
| Loss before income tax | (23,879) | (130,880) |
| Income tax provision | (314) | (331) |
| Net loss | (24,193) | (131,211) |
| Other comprehensive income (loss): | ||
| Unrealized gain on available-for-sale securities | 22 | 9 |
| Unrealized loss on pension plans | (5) | (103) |
| Other comprehensive income (loss) | 17 | (94) |
| Comprehensive loss | $(24,176) | $(131,305) |
| Net loss per share, basic and diluted | $(2.45) | $(20.94) |
| Weighted average shares of common stock, basic and diluted | 9,884,955 | 6,264,612 |
Consolidated Statements of Changes in
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.